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Trademark Enforcement of Counterfeit Drugs: A Guardian of the Rich and
Poor Alike
Melanie Magdun
“It rains on rich and poor alike, but the rich have better umbrellas” 1
INTRODUCTION
Undoubtedly, the pharmaceutical industry, both within the United States
and globally, is significant to a large portion of the population. “Pharmaceuticals
save lives, relieve suffering, and promote the quality of life for those with access to
them.” 2 In 2019, United States spending on pharmaceuticals topped $500 billion, 3
and the global market is predicted to exceed $1.5 trillion annually by 2023. 4 “About
46 percent of the U.S. population used one or more prescription drugs in the past 30
days.” 5 While this is a sizeable portion of the population, even more Americans are
purchasing over-the-counter (OTC) medicines. 6 On average, United States
consumers make twenty-six trips a year to purchase OTC products, and United
States households spend about $338 per year on OTC medicines. 7 When going to a
store, doctor’s office, or pharmacy, a consumer wants to be able to trust that the
medicine they are receiving is the medicine they intend to take. This intention can
lead consumers to choose trusted brand names over generic products, even though
the generic is normally the cheaper option. 8
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Entry From April 26, 2015, BARRY POPIK (Apr. 26, 2015),
https://www.barrypopik.com/index.php/new_york_city/entry/it_rains_on_rich_and_poor_alike.
Bryan A. Liang, A Dose of Reality: Promoting Access to Pharmaceuticals, 8 WAKE FOREST INTELL. PROP. L.J.
301, 301 (2007).
Eric M. Tichy, James M. Hoffman, Katie J. Suda, Matthew H. Rim, Mina Tadrous, JoAnn Stubbings,
Sandra Cuellar, John S. Clark, Michelle D. Wiest, Linda M. Matusiak, Robert J. Hunkler, & Lee C.
Vermeulen, National Trends in Prescription Drug Expenditures and Projections for 2020, AM. J. HEALTH
SYS. PHARMACISTS, 1213, 1214 (2020).
The Global Use of Medicine in 2019 and Outlook to 2023, IQVIA INST. (Jan. 29, 2019),
https://www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicine-in-2019-and-outlookto-2023.
Shelly Hagan, Nearly One in Two Americans Takes Prescription Drugs: Survey, BLOOMBERG (May 8, 2019),
https://www.bloomberg.com/news/articles/2019-05-08/nearly-one-in-two-americans-takes-prescriptiondrugs-survey (citing a 2015–2016 survey from the National Center for Health Statistics).
See Statistics on OTC Use, CONSUMER HEALTHCARE PRODS ASS’N, https://www.chpa.org/about-consumerhealthcare/research-data/otc-use-statistics (last visited Nov. 19, 2019).
Id.
See Lauren Friedman, Here's Why You Should Always Buy Generic Drugs, BUS. INSIDER (May 6, 2014),
https://www.businessinsider.com/generic-drugs-vs-brand-name-2014-5 (explaining the problems with the
negative perception of generic medicine and how this hurts the consumer); see also Keri Sewell, Susan
Andreae, Elizabeth Luke, & Monika M. Safford, Perceptions of and Barriers to Use of Generic Medications
in a Rural African American Population, Alabama, 2011, CTRS. FOR DISEASE CONTROL (Aug. 30, 2012),
https://www.cdc.gov/pcd/issues/2012/12_0010.htm (explaining how previous studies show that
disadvantaged people, who may particularly benefit from cost savings, have low trust of generics and
increased reluctance to switch to generics).
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Despite their attempts to get the best and most trusted drugs, consumers’
efforts can still be thwarted, and people can end up receiving fake medicines.
Counterfeit goods, such as copies of luxury clothing or accessories, only mislead the
customer but result in no actual harm, unlike the possible effects of taking a fake
pharmaceutical. 9 The growing counterfeit drug market has vast implications on
both personal and public health for people across the globe, 10 so much so that it has
been “regarded as murder or terrorism and the greatest evil against human health
and economy.” 11
The issues surrounding counterfeit drugs have been written about
extensively, and papers commonly explore the inadequacies in current laws,
enforcement of those laws, and penalties for counterfeiters. 12 Understanding these
three aspects is important for the supply side of this issue, but the demand side is
tantamount in importance as consumer need is “the root of the problem,” and
consumers are ultimately the ones receiving the counterfeit products. 13 Consumers
have the power to decide what to purchase but will purchase what they can afford
and what they trust. To ensure the medicines sold to customers are legitimate,
governments and companies need to strengthen regulations and enforce intellectual
property rights—specifically trademarks—while balancing this increased protection
with reasonable prices that consumers will actually be able to afford.
This Note will explore the history and current state of the counterfeit drug
crisis within developing countries as compared to the United States. This drug crisis
is truly a global issue and not isolated to one country. As supply chains get more
complicated with international production and shipping, there is a higher likelihood
that counterfeit goods will enter the global supply chain and ultimately reach the
consumer. Part I explains the nuances of the problem in different regions across the
globe and shows that certain populations, such as women, children, and the elderly,
are more likely to be affected by counterfeit drugs. Part II examines previous
attempts, both within specific regions and internationally, to ameliorate the
situation by using treaties and intellectual property protection. Part III explores
trademark protection within the pharmaceutical industry, why this is the type of
intellectual property we should be focusing on with this issue, and how stronger
enforcement could lead to fewer counterfeit drugs.

9
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11

12

13

Sandra L. Rierson, Pharmaceutical Counterfeiting and the Puzzle of Remedies, 8 WAKE FOREST INTELL.
PROP. L.J. 433, 434–35 (2007).
Joel Breman, It’s Time to Stop Murder by Counterfeit Medicine, STAT (May 7, 2019),
https://www.statnews.com/2019/05/07/stopping-murder-counterfeit-medicine.
Linus Mhando, Mary B. Jande, Anthony Liwa, Stanley Mwita, & Karol J. Marwa, Public Awareness and
Identification of Counterfeit Drugs in Tanzania: A View on Antimalarial Drugs, 2016 ADVANCES PUB.
HEALTH 1, 2.
Robert C. Bird, Counterfeit Drugs: A Global Consumer Perspective, 8 WAKE FOREST INTELL. PROP. L.J. 387,
388 (2007).
Id. (explaining “how the supply side of fake drugs can be curtailed through a combination of governmental
and industry actions.”).
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I. THE COUNTERFEIT DRUG PROBLEM
A. Defining the Problem
The issue of counterfeit drugs is not new to society; there are references to
supplies of fake antimalarial medicines with fake cinchona bark in the early 1600s,
and more recently, counterfeit quinine in the 1800s. 14 Today, the presence of fake
medicine, in general, is an increasingly tenacious public health issue across the
globe. 15 Because this is a global issue and affects different regions and countries in
various ways to varying degrees, there has not been an international consensus on
the definition of a counterfeit drug. 16 The scope and definition of the counterfeit
drug crisis have evolved over the last few decades as the issue has become more
prevalent and well-known. The World Health Organization (WHO) previously
defined a counterfeit drug as a medicine that is “deliberately and fraudulently
mislabelled with respect to identity and/or source.” 17 This definition has evolved as
the WHO tried to simplify it by creating three categories of harmful drugs: (1)
“falsified medical products deliberately misrepresent their identity and are
distributed with criminal intent”; (2) “substandard medical products fail to meet
quality standards”; and (3) “unregistered or unlicensed medical products have not
been assessed or approved.” 18 Each of these categories comes with ways that harm
could potentially manifest for the consumer; the counterfeit drugs could not only
waste their money but can also have serious implications to their health. 19
The first category, which covers falsified medical products, is the focus here.
For this first category, the patient will not be treated for their disease or condition
as the medicine will often be a different type of drug or a placebo with no active
ingredient. 20 Some studies estimate that “up to 76 percent of the counterfeit drugs
on the [global] market contain either no active ingredient or incorrect ingredients,
with 10 to 15 percent containing [some type of] contaminants.” 21 Those that simply
lack an active ingredient but are not contaminated might not directly harm the

14
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Paul N. Newton, Michael D. Green, & Facundo M. Fernández, Impact of Poor-Quality Medicines in the
‘Developing’ World, 31 TRENDS PHARMACOLOGICAL SCI. 99, 99 (2010).
Amanda Chaves, A Growing Headache: The Prevalence of International Counterfeit Pharmaceutical Trade
in Developing African Nations, 32 SUFFOLK TRANSNAT’L L. REV. 631, 633 (2009).
Victoria Rees, The Impact of Counterfeit Drugs in South and South-East Asia, EUR. PHARMACEUTICAL REV.
(July 3, 2019), https://www.europeanpharmaceuticalreview.com/article/92194/the-impact-of-counterfeitdrugs-in-south-and-south-east-asia/.
Id.
Breman, supra note 10.
Erwin A. Blackstone, Joseph P. Fuhr, Jr., & Steve Pociask, The Health and Economic Effects of Counterfeit
Drugs, 7 AM. HEALTH & DRUG BENEFITS 216, 221 (2014).
Liang, supra note 2, at 305–06; see Rick Roberts, Counterfeit Biologics: A Personal Narrative, 10 J. BIOLAW
& BUS. 37, 38 (2007) (describing fake growth hormone substituted with human chorionic gonadotropin, a
female steroid); see also Blackstone et al., supra note 19.
Amy M. Bunker, Deadly Dose: Counterfeit Pharmaceuticals, Intellectual Property and Human Health, 89 J.
PAT. & TRADEMARK OFF. SOC’Y 493, 496 (2007).
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patient, but taking these drugs can result in the patient failing to be treated and
could lead to future health implications, such as resistance to antibiotics. 22
Other situations are much more perilous as they can introduce dangerous
substances to the body that could lead to death or serious injury. Manufacturers of
these illegal drugs are concerned with maximizing profits and generally disregard
the safety of the medicine they are making, which can lead to drugs being made
from a wide variety of toxic or poisonous materials. 23 Some examples of these
harmful ingredients include “bacteria-laced water, toxic yellow paint, floor wax,
colored dye, powdered cement, boric acid, and antifreeze.” 24 One specific example
was a counterfeit case of the blood thinner heparin that caused as many as eightyone deaths and resulted in a nationwide recall after it was discovered that the
active ingredient was replaced with a cheaper substance that originated in China. 25
Other times, the manufacturer may use the right drug, but it either uses less
of the drug to save money or makes it incorrectly for a variety of reasons, which
leads to the wrong concentration or dose of the drug. 26 This can also lead to death
or cause severe complications for patients. 27 Finally, the fake medicine might not
contain the wrong dose or contaminants, but it might just be the wrong drug
altogether. 28 For example, the weight-loss medication Alli has been counterfeited
with a fake version that contains the controlled substance sibutramine instead of
orlistat; and the Food and Drug Administration (FDA) reported that this substance
could produce harmful interactions with other medications a patient may be
taking. 29
The types of counterfeit drugs have also shifted throughout the decades and
now span a wider variety—ranging from “lifestyle drugs to lifesaving drugs.” 30
Early on, the focus was on lifestyle drugs for things such as “diet, erectile
dysfunction, and hair growth pills.” 31 Detection has since shifted to more serious
lifesaving drugs including “anti-arthritis drugs, antibiotics, antihistamines, anti22

23
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Blackstone et al., supra note 19, at 218. A doctor may end up prescribing stronger antibiotics if they believe
the original prescription was not working, when in reality, the patient could have never received any actual
antibiotics. See also Ben Hirschler, Tens of Thousands Dying from $30 Billion Fake Drugs Trade, WHO
Says, REUTERS (Nov. 28, 2017) https://www.reuters.com/article/us-pharmaceuticals-fakes/tens-of-thousandsdying-from-30-billion-fake-drugs-trade-who-says-idUSKBN1DS1XJ.
Bunker, supra note 21, at 496–97.
Blackstone et al., supra note 19, at 218 (explaining how children died after taking acetaminophen syrup to
remedy a cough but the medicine had been made with glycerol contaminated with ethylene glycol, an
ingredient in antifreeze).
Id.
Id.
Id. (“One example of this is the case of a physician who was supplied with a research version of
onabotulinumtoxinA (Botox) that was much more concentrated than the real medicine, and is not intended
for human use. This resulted in respiratory paralysis and near death for several patients, including the
physician who was using it himself.”).
Id.
Id.
Liang, supra note 2, at 305.
Id.; Jessica McLaughlin, The United States Isn’t Immune to Counterfeit Drugs, LAW STREET (May 8, 2015),
https://www.lawstreetmedia.com/issues/health-science/united-states-isnt-immune-to-counterfeit-drugs/.
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parasitic drugs, AIDS/HIV therapy, cancer drugs, cardiac drugs, cholesterol drugs,
flu medications, hormone replacement therapy, insulin, over-the-counter pain
medications, and many more.” 32 For example, in 2012, the FDA discovered that two
lots of an imported cancer medicine were counterfeit and contained none of the
active ingredient and instead contained salt and starch. 33 This shift is important to
note as it affects people with life-threatening diseases. 34 If a person takes a placebo
diet pill, they have most likely just wasted their money and will not get any help
losing weight from the pill; however, if a doctor administers antimalarial medicine
to a patient that turns out to be fake, the patient could die from not receiving the
medicine they needed. Additionally, this issue extends beyond just medicine and
impacts a variety of health-related products. For example Homeland Security
Investigations agents recently removed over 300 counterfeit contact lenses from a
store in Texas. 35 This is particularly concerning as sixty percent of counterfeit
lenses tested positive for microbial contamination, which could lead to serious
infections, or even blindness, due to diseases such as microbial keratitis and
bacterial endophthalmitis. 36
B. The Counterfeit Drug Market
The market for counterfeit drugs is neither new nor insignificant—it has
matured, expanded, and shifted. This expansion was spurred by the rapid growth of
the pharmaceutical market in general. 37 The industry that is now worth $1.2
trillion 38 has grown incredibly quickly in the past few decades. Likewise, the growth
of the counterfeit market has paralleled the rapid growth of the pharmaceutical

32
33

34

35
36
37
38

Liang, supra note 2, at 305; see also Bunker, supra note 21, at 496 (“In 2003, for example, the WHO stated
that half of the reported cases of counterfeit drugs involved antibiotics.”).
Eric Palmer, Feds Nail Key Player in Counterfeit Avastin Probe, FIERCEPHARMA (Apr. 24, 2013, 9:09 AM),
www.fiercepharma.com/story/feds-nail-key-player-counterfeit-avastin-probe/2013-04-24.
See, e.g., Charles Bennett, Government Agencies and Pharmaceutical Industry Must Take Action to Thwart
Sales of Counterfeit Drug Products, CANCER NETWORK, (Sept. 1, 2006),
https://www.cancernetwork.com/articles/government-agencies-and-pharmaceutical-industry-must-takeaction-thwart-sales-counterfeit-drug (explaining a situation where a patient was being treated for anemia
following a liver treatment and received eight weeks of counterfeit medicine instead of the lifesaving
medicine he needed); see also 1 in 10 Medical Products in Developing Countries is Substandard or Falsified,
WORLD HEALTH ORG., (Nov. 28, 2017), https://www.who.int/news-room/detail/28-11-2017-1-in-10-medicalproducts-in-developing-countries-is-substandard-or-falsified (“Since 2013, the WHO has received 1500
reports of substandard or falsified products.” The most frequently reported products were antimalarial
medicines and antibiotics).
Busted: Feds Seize Hundreds of Illegal, Counterfeit Contact Lenses, AM. OPTOMETRIC ASS’N (Oct. 31, 2019),
https://www.aoa.org/news/advocacy/homeland-security-agents-bust-counterfeit-contact-lens-dealers.
Id.
See Bunker, supra note 21, at 494.
Global Pharma Spending Will Hit $1.5 Trillion in 2023, Says IQVIA, PHARMACEUTICAL COM. (Jan. 29,
2019), https://pharmaceuticalcommerce.com/business-and-finance/global-pharma-spending-will-hit-1-5trillion-in-2023-says-iqvia/ (referencing the Global Use of Medicines report from the IQVIA Institute for
Human Data Science).
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industry. 39 “The National Association of Boards of Pharmacy estimated that
counterfeit drugs generated $75 billion in revenues in 2010,” 40 with estimates of it
now being worth around $200 billion, making the counterfeit pharmaceutical
market almost as valuable as the illicit drug trade. 41 Further, this rapid growth is
not predicted to stop, but is predicted “to grow by twenty percent annually” and is
currently “growing at twice the rate of legitimate pharmaceuticals.” 42
The size of the counterfeit market is exacerbated by the following: the high
price of name brand pharmaceuticals, the shortages of important drugs, the rise of
online pharmacies, convoluted supply chains, low penalties for those who are caught
selling counterfeit drugs, and the low cost of manufacturing the fake medicines.
There is a relationship between products associated with high prices, such as luxury
goods, pharmaceuticals, and copyrighted media, and consumer demand for
counterfeit products. 43 Part of the reason for the high costs of pharmaceutical drugs,
especially those without a generic version, are the intellectual property rights that
the companies maintain on the medicines, primarily patents and their associated
monopoly pricing. 44 For the limited term of the patent, the company can price the
drug at higher prices as there are no other companies selling the drug or a generic
version. 45 The drugs need to be priced higher to recoup the costs of drug
development—twenty percent of drugs approved by the FDA generate seventy
percent of the returns for pharmaceutical companies. 46 This demand for counterfeit
medicines created by high drug prices is further increased when crucial drugs are in
short supply as consumers may be more desperate for the medicine. 47 Consumers
will either have to pay the high price for the drug if they can access it or search
beyond their normal markets for a cheaper source, such as an online pharmacy,
which increases the chance they will receive a counterfeit. 48
39

40
41

42
43

44
45
46
47

48

See Kim Overstreet, $200 Billion Pharma Counterfeit Drug Market Growing by 20% Per Year, PACKAGING
WORLD (Nov. 26, 2019), https://www.packworld.com/home/article/21102806/200-billion-pharma-counterfeitdrug-market-growing-by-20-per-year (“This alarming growth is twice the rate of the legitimate
pharmaceutical market, and accounts for 2.5% of the total global pharma market.”).
Blackstone et al., supra note 19, at 219.
Kristina Acri, They Cost Us Billions and They Can Kill: Counterfeit Drugs are Invading Canada, FIN. POST
(Mar. 2, 2018), https://business.financialpost.com/opinion/they-cost-us-billions-and-they-can-kill-counterfeitdrugs-are-invading-canada (noting that the illicit drug trade was worth $246 billion in 2013).
Id.
Susan K. Sell, TRIPs Was Never Enough: Vertical Forum Shifting, FTAS, ACTA, and TPP, 18 J. INTELL.
PROP. L. 447, 459–60 (2011).
Liang, supra note 2, at 322.
See id. at 103, 322.
Id. at 322–23.
Blackstone et al., supra note 19, at 221; see also Hannah Balfour, Chinese Police Seize Over 3,000 Fake
COVID-19 Vaccines, EUR. PHARMACEUTICAL REV. (Feb. 8, 2021),
https://www.europeanpharmaceuticalreview.com/news/142118/chinese-police-seize-over-3000-fake-covid-19vaccines/ (explaining how manufactures of counterfeit COVID-19 vaccines are exploiting people who are
desperate to receive the in-demand vaccine).
Blackstone et al., supra note 19, at 221; see also Louisa Wright, Officials Warn of Fake COVID-19 Vaccines,
DEUTSCHE WELLE (Jan. 4, 2021), https://www.dw.com/en/officials-warn-of-fake-covid-19-vaccines/a-56123830
(explaining how fake vaccines for COVID-19 are being sold online which is dangerous and the large demand
for the vaccine is triggering criminal activity).
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Those who are manufacturing fake drugs are the only winners in this story.
Consumers are ripped off or injured, drug companies lose profits, and drug
development and research are stifled. The culprits do not have to meet the quality
standards of normal, legitimate drug manufacturers, market their product, worry
about securing intellectual property rights, engage in years of costly research, or
partake in any of the other expensive and time-intensive steps that a real drug
company goes through to get their product on the market. 49 They can “free-ride” off
of an established brand and make the fake product for twenty percent of what it
costs legal manufacturers. 50 They can use whatever ingredients they have on hand
and make a significant return on investment without needing much skill. 51
Furthermore, this market is so profitable and successful that it is “more lucrative
than the narcotics business because counterfeit drugs are worth more than illicit
drugs.” 52 One expert estimates that investors can earn up to thirty times their
investment on prescription drugs, which is a staggering ten times the profit rate of
trafficking heroin. 53 Coupled with the possibility of these large profit margins is a
small chance of facing prosecution. 54 While each country has its punishments, it is
difficult for the United States to prosecute foreign nationals for this crime. 55
The counterfeit drug market also has implications on legitimate
pharmaceutical companies and can deprive society of potential future drugs. It goes
beyond just lost revenue for these companies. They are forced to spend their money
monitoring their supply chain, investing in anti-counterfeiting technologies, trying
to repair their reputations, and dealing with liability risks. 56 Counterfeit drugs can
also lead to lawsuits for pharmaceutical companies. For example, in the heparin
case discussed earlier, the company that sold the drug was subject to over 700
lawsuits as a result of the counterfeit ingredients causing deaths for consumers. 57
With more money being spent trying to fix these issues, there are fewer resources
for research and development of future drugs. 58 With less investment in research,
there are fewer discoveries and new medicines for diseases, causing many people
around the world to suffer or die at the hands of these copycat drug

49

50
51
52
53

54
55
56
57
58

Bird, supra note 12, at 393–94 (citing Natasha Wong, Counterfeit Medicine: Is it Curing China?, 5 ASIANPAC. L. & POL’Y J. 155, 171 (2004) (“[The counterfeit pharmaceutical distributor] will make a substantial
profit based upon his non-existent research and development, lack of advertising costs, and dependence
upon the public’s trust of the name brand’s product reputation, which he is taking advantage of with
counterfeit goods.”).
Id.
Bunker, supra note 21, at 507.
Acri, supra note 41.
See Blackstone et al., supra note 19, at 220; see also Rachel Ehrenberg, Counterfeit Crackdown, SCI. NEWS
(June 3, 2011, 10:50 AM), https://www.sciencenews.org/article/counterfeit-crackdown.
Bunker, supra note 21, at 507.
Counterfeit Medicine in America: 2018, PARTNERSHIP FOR SAFE MEDS. (Oct. 29, 2018),
https://www.in.gov/bitterpill/files/Safdar-Counterfeit-IN-AG-Opioid-Summit-2018-10-29-FINAL.pdf.
Acri, supra note 41.
Blackstone et al., supra note 19, at 217.
Acri, supra note 41.
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manufacturers. 59 Drugs are already very expensive to develop—a new prescription
medicine is estimated to cost the drug maker around $2.6 billion. 60 If drugs are this
expensive to develop and companies are worried their work will just be
counterfeited, there is even less incentive for companies to invest in producing new
drugs. 61
C. Counterfeit Drugs in the United States
The United States is not immune to the effects of fake medicines, even
though it has the safest drug supply in the world. 62 The United States has managed
to do a good job protecting its consumers from fake drugs through “combined efforts
of the U.S. government, the U.S. pharmaceutical industry, and local authorities
world-wide” that disrupt the counterfeit drug operations. 63 Despite these efforts,
however, some counterfeit drugs still manage to make it into the country, and
Americans are largely unaware of the threat these medicines pose to their society. 64
One study showed that a mere twelve percent of Americans feel they have enough
information on counterfeit medicines, and in most cases, are more likely to associate
counterfeiting with consumer goods rather than medicines. 65 Each year as many as
nineteen million people in the United States purchase medicine outside the normal
manufacturer-to-supplier direct supply chain and use online pharmacies or other
unconventional sources instead. 66 Ten percent of drugs distributed each year are
not distributed by national wholesalers to the end supplier, such as the pharmacy or
hospital. 67 This is where the issues arise. The domestic drug supply has been
relatively immune to the counterfeit issue, but the fake drugs managed to make it
into the hands of American citizens through numerous breaks in the supply chain,
with many of the drugs having international origins. 68 A recent report showed that
nearly forty percent of drugs in the United States are manufactured overseas, and
around eighty percent of the active ingredients for the drugs manufactured on
American soil are imported from abroad. 69
59
60

61
62
63
64
65
66
67
68
69

Bunker, supra note 21, at 494, 515.
Thomas Sullivan, A Tough Road: Cost to Develop One New Drug is $2.6 Billion; Approval Rate for Drugs
Entering Clinical Development is Less Than 12%, POL’Y & MED. (Mar. 21, 2019),
https://www.policymed.com/2014/12/a-tough-road-cost-to-develop-one-new-drug-is-26-billion-approval-ratefor-drugs-entering-clinical-de.html.
Bunker, supra note 21, at 494.
Counterfeit Medicine in America: 2018, supra note 55.
Bunker, supra note 21 at 506.
Counterfeit Medicine in America: 2018, supra note 55.
Perceptions of Counterfeit Medicines: Only 12% of Americans Feel They Have Enough Information, SANOFI
(Nov. 20, 2015), http://www.multivu.com/players/English/7697951-sanofi-counterfeit-medicines.
Counterfeit Medicine in America: 2018, supra note 55.
Blackstone et al., supra note 19, at 218.
Liang, supra note 2, at 309.
Memorandum from the U.S. House of Representatives, Comm. on Energy & Commerce., Majority Comm.
Staff to Members, Subcomm. on Oversight and Investigations. (Feb. 25, 2014) (on file with the House of
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As the supply chain grows, so does the chance of counterfeits being
introduced into the chain. The drug Epogen, for example, caused extreme health
issues for a patient who just underwent a liver transplant; it had a convoluted
supply chain that included at least thirteen chains of ownership and was handled
by the manufacturer, the major distributor, “3 different wholesalers, 2 pharmacies,
4 unlicensed go-betweens, and 1 suspected counterfeiter.” 70 While this specific drug
was purchased from a pharmacy, there are times when consumers will turn to
sources beyond the norm for their drugs, specifically when there are drug
shortages. 71 The complex supply chains and drug shortages exacerbate this issue. In
short, “[s]hortages of key medicines in the US and Europe have created new
opportunities for illicit traders, while ever-longer manufacturer supply chains open
the door to diversion and theft.” 72
One example of people going beyond the normal market is when United
States citizens ignore federal law and cross the border to purchase drugs from
Canada or Mexico, or alternatively, purchase drugs online. 73 Discussed later, Asian
countries are the biggest culprits in the production of fake drugs, 74 but Mexico is a
threat due to its proximity to the United States and an abundance of fake drugs. 75
While this should be concerning for Mexican citizens, it also affects Americans who
decide to purchase drugs while abroad due to the high cost or shortage in their
home country. This market is significant in size as one estimate approximated that
Americans spend upwards of $800 million a year on pharmaceuticals from Mexico. 76
The issues from Canada come less from actually crossing the border and
instead present themselves in the form of online pharmacies, which have been on
the rise with approximately 35,000 of them appearing over the last decade. 77 The
FDA estimates that about twenty-five percent of internet users have purchased
medicine online. 78 Overall, Americans are not aware of the dangers they face when
purchasing drugs from these pharmacies and do not realize they could be receiving
fake medicine. 79 These websites will pretend to be Canadian pharmacies, but this is

70
71
72
73

74
75

76
77
78
79

Representatives Document Repository, http://docs.house.gov/meetings/IF/IF02/20140227/101804/HHRG113-IF02-20140227-SD002.pdf).
Blackstone et al., supra note 19, at 218.
See id. at 218–19.
Id. (quoting Jill Wechsler, Campaign Mounts to Curb Counterfeit Drugs, 25 BIOPHARM INT’L 40 (2012)).
Bernard Wolfson, Here’s What Can Go Wrong When You Shop in Mexico and Canada for Cheap Drugs, L.A.
TIMES (Aug. 19, 2019, 12:05 PM), https://www.latimes.com/business/story/2019-08-19/shop-mexico-canadacheap-drugs.
See infra Part I.D.
See, e.g., DEA Issues Warning Over Counterfeit Prescription Pills from Mexico, U.S. DRUG ENFORCEMENT
ADMIN. (Nov. 4, 2019), https://www.dea.gov/press-releases/2019/11/04/dea-issues-warning-over-counterfeitprescription-pills-mexico-0 (warning Americans of the dangers of counterfeit drugs from Mexico and
explaining how twenty-seven percent of the drugs sampled contained potentially lethal doses of fentanyl).
Marv Shepherd, Drug Quality, Safety Issues and Threats of Drug Importation, 36 CAL. W. INT’L L.J. 77, 80
(2005).
Breman, supra note 10.
Blackstone et al., supra note 19, at 219.
Id.

290

Indiana Journal of Law and Social Equality

[9:281

often a hoax; less than two percent “claiming to be Canadian were actually
registered in Canada,” while the remaining were actually registered to other
countries across the world. 80 Customers turn to these websites to save money and
are attracted to claims boasting savings up to seventy-five percent, but they are
potentially losing and wasting money on medication that will, at best, do nothing for
them and, at worst, kill them. 81 Further, eighty-eight percent of the “most
commonly prescribed generic drugs can be purchased more cheaply in the U.S. than
from Canadian pharmacies.” 82 Beyond the economic and personal health threats
these websites pose, it has been found that some of them are actually “linked to
terrorist groups, such as Hezbollah and Al Qaeda, and others are linked to
organized crime––posing a threat to national and international security.” 83
Once again, the power here lies in the consumer and their beliefs. American
consumers often do not see the dangers that come with shopping online for medicine
or the re-importation of drugs from Canada. 84 If the possibility of receiving fake
medicine from Canada is worth the risk, the consumer should first check cipa.com, a
website run by the Canadian International Pharmacy Association, to check if the
seller’s website is legitimate. 85 While it is still currently illegal to get drugs this
way, the Trump administration considered opening up drug importation from
Canada. 86 This would have allowed states to import medicine from Canada but is
not guaranteed to get consumers cheaper or safer drugs. 87 This would have
implications on the supply stream, which, as previously discussed, is already
susceptible to being comprised and infiltrated with counterfeit drugs. Overall, the
United States is not immune to the effect of counterfeit drugs, but the high prices
forced on its consumers cause them to seek potentially dangerous sources for their
medicine.
D. The Problem is Intensified in Developing Countries
“According to the WHO, 1 in 10 medical products in developing countries is
falsified or substandard.” 88 Some argue that this exact percentage and the true
80
81

82
83
84
85
86

87
88

Id.
Id. at 220 (“Tap water or bacteria at a discount of 75% off the price of the legitimate drug is no bargain for
anyone.”).
Wolfson, supra note 73.
Blackstone et al., supra note 19, at 220.
Id. at 219.
Wolfson, supra note 73.
Id. (“Despite the official prohibition, FDA guidelines allow federal agents to refrain from enforcement ‘when
the quantity and purpose are clearly for personal use, and the product does not present an unreasonable
risk to the user.’”); Noam Levey, Trump Administration to Consider Plans to Import Prescription Drugs
from Canada, L.A. TIMES (July 31, 2019), https://www.latimes.com/politics/story/2019-07-31/trumpadministration-drugs-canada.
Levey, supra note 86.
Breman, supra note 10; WORLD HEALTH ORG., supra note 34 (explaining an analysis of 100 studies from
2007 to 2016, covering more than 48,000 samples, that showed 10.5 percent of drugs in low and middleincome countries to be fake or substandard).

2021]

Trademark Enforcement of Counterfeit Drugs

291

impact on the pharmaceutical market is hard to establish on a country and global
scale, but the numbers consistently indicate that developing countries are the most
affected by the counterfeit drug problem. 89 For example, in Africa and parts of Asia,
up to sixty percent of the drugs could be counterfeit. 90 Counterfeit rates of drugs in
these countries are high for several reasons. First, developing countries often do not
have the money or resources to (1) monitor and regulate the supply chain and (2)
test to see if the medicine is authentic. 91 “Expensive analytic equipment generally
isn’t available, while simple, accurate, and inexpensive testing systems for use in
the field, at pharmacies, and at the point of care remain out of reach in virtually all
poor countries.” 92 Second, the laws, enforcement of regulations, and judicial actions
for identified criminals are poorly defined. 93 Sometimes the proper officials are in
place, but corruption leads to them being bypassed and allows counterfeits to slip
through. 94 Consumers play a role, as they often lack knowledge about fake drugs
and often need drugs that are in short supply. 95 Finally, these countries not only
lack the needed laws and resources to tackle this issue, but they are also busy
handling other crimes. For example, in one survey, counterfeiting was connected to
organized crime nearly thirty percent of the time and drug crimes forty percent of
the time. 96 The two areas of the world most affected by this are parts of Asia and
Africa, with sales of fake medicines amounting to $5 billion per year. 97 These
regions are the perfect target for counterfeiters, as up to sixty percent of essential
medicines are not available to the people there, causing the drugs to be in extremely
high demand. 98 The rest of this section will examine these regions and how their
mostly poor populations must deal with major public health crises in very prevalent
and growing counterfeit drug markets. 99
There are more detected cases of counterfeit drugs in Africa than in any other
region of the world. 100 Along with the reasons mentioned above, these counterfeit
89
90
91
92
93
94
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97
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100

Bunker, supra note 21, at 497.
Mhando et al., supra note 11.
See Breman, supra note 10.
Id.
Id.
African Policymakers Must Pay More Attention to Counterfeit Drugs, INST. FOR SECURITY STUD. (Jan. 25,
2019), https://issafrica.org/about-us/press-releases/african-policymakers-must-pay-more-attention-tocounterfeit-drugs.
Bunker, supra note 21, at 496.
The Illicit Trafficking of Counterfeit Goods and Transnational Organized Crime, UNITED NATIONS OFF. ON
DRUGS & CRIME,
https://www.unodc.org/documents/counterfeit/FocusSheet/Counterfeit_focussheet_EN_HIRES.pdf.
(“Evidence suggests that criminal networks use similar routes and modus operandi to move counterfeit
goods as they do to smuggle drugs, firearms and people.”).
Id.
98 See Sheila Mysorekar, Silent Murder, DEV. & COOPERATION (Mar. 14, 2013),
https://www.dandc.eu/en/article/medicines-are-too-expensive-poor-people-developing-countries-localproduction-could-make.
Bunker, supra note 21, at 499.
African Policymakers Must Pay More Attention to Counterfeit Drugs, supra note 94.
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drugs are especially prevalent in Africa due to the desire for affordable medicine, so
much so that even some pharmacists admit to purchasing medicine from the
cheapest, but not always the safest, drug suppliers. 101 Furthermore, many African
nations are led by corrupt governments that either fail to regulate the counterfeit
market or sympathize with small business owners even if they are “engaging in the
counterfeit drug trade.” 102 The types of drugs counterfeited in Africa are most
commonly crucial, life-saving drugs for diseases such as malaria. 103 For every one
million people who die from malaria, up to forty-five percent of the deaths were
affected by counterfeit medicine. 104 One WHO report estimated that “at least 72,000
children die of pneumonia and 69,000 people die of malaria each year as a result of
falsified or substandard treatments.” 105 While counterfeit drugs have been an issue
in Africa for decades, the issue is not likely to go away anytime soon, especially due
to the incredible growth rate of the continent’s pharmaceutical market. 106 It was
predicted that the market would triple and reach $65 billion by 2020. 107 As Africa
becomes more popular for pharmaceutical companies, it will begin to attract
additional counterfeiters. 108
Currently, Africa’s problems with counterfeits are unlikely to go away unless
they are cut off at the source—Asia. The problem is so severe that in just two weeks,
the World Customs Organization (WCO) stopped over 100 million counterfeit drugs,
which is “just a drop in the ocean,” from entering Africa from Asian
manufacturers. 109 Asia is less directly impacted by being infiltrated with counterfeit
drugs, but rather, is the biggest culprit in the production of the medicines, with
ninety-seven percent coming from China or India. 110 As mentioned before, it is hard
to get exact statistics on this issue, so it is difficult to say which country is the
biggest culprit. One study found that up to three out of every four counterfeit drugs
originate in India, 111 while others believe that China is the largest producer of these
101
102
103

104
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107
108

109

110
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Hirschler, supra note 22.
Chaves, supra note 15, at 639.
See Fake Pharmaceuticals: Bad Medicine: The World’s Drug Supply is Global. Governments Have Failed to
Keep Up, ECONOMIST (Oct. 13, 2012), http://www.economist.com/node/21564546 (stating that, in 2011, 64%
of antimalarial drugs in Nigeria were found to be counterfeit).
Mhando et al., supra note 11.
Rae Ellen Bichell, Fake Drugs Are a Major Global Problem, WHO Reports, NPR (Nov. 29, 2017, 4:58 PM),
hhttps://www.npr.org/sections/goatsandsoda/2017/11/29/567229552/bad-drugs-are-a-major-global-problemwho-reports.
Amindeh Blaise Atabong, African Healthcare Systems Are in an Arms Race with a Rising Fake Medicine
Problem, QUARTZ AFR. (Apr. 23, 2019), https://qz.com/africa/1601659/africas-counterfeit-drug-problem-beingtackled-by-innovators/.
Id.
Id.; African Policymakers Must Pay More Attention to Counterfeit Drugs, supra note 94 (“Currently, only 37
out of 54 African states have some level of pharmaceutical production, but as new, legitimate firms enter
these markets, so will additional counterfeiters.”).
Cécile Barbière, Counterfeit Chinese and Indian Drugs Invade Africa, EURACTIV (Jan. 24, 2017),
https://www.euractiv.com/section/health-consumers/news/counterfeit-chinese-and-indian-drugs-invadeafrica/.
Id.
Mhando et al., supra note 11.
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drugs. 112 Other smaller countries “such as Myanmar, Cambodia, Indonesia, and
Thailand are beginning to manufacture fake pharmaceuticals.” 113 While these
countries are less likely to produce the pharmaceuticals (only two percent of the
drugs come from Southeast Asia), 114 they play a significant role in the transport of
the drugs as major transit points in the process. There are three main reasons why
these countries are ideal for transporting fake pharmaceuticals: (1) the countries
are all well connected physically; (2) free-trade agreements ease transport without
legal barriers; 115 and (3) many of these countries have major ports, which is
convenient as “50-60 percent of illicit traffic is shipped via sea.” 116
E. At-Risk Populations Affected by This Crisis
“[R]esearch findings clearly show that the poorest and most vulnerable
populations suffer the most.” 117 The elderly, children, women, and the poor have all
faced serious consequences from fake medicine. While developing countries, as just
discussed, are more likely to be affected, those with less money in any country are
at a greater risk of being exposed to counterfeit drugs. While the affluent could still
receive a fake drug that sneaks its way into the supply stream, they are less likely
to stray from the normal sources to get their medicines. 118 Those with less money
may feel like they have no option other than to go online, or even to another
country, to get their medicine at an affordable price. 119 This is frequently seen with
senior citizens in America who go on trips to Mexico to buy prescription drugs. 120
Children are also frequently the victims of this crime. Children cannot control the
medicine they are given, are not informed about these problems, and do not choose
where their medicine comes from. One horrifying example of this was when “[m]ore
than 500 children around the world died from counterfeit cough syrup that was
tainted with ethylene glycol,” commonly known as antifreeze. 121 Another tragic case
involved inhalers that were contaminated with bacteria and used to treat children

112
113
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115
116
117
118

119
120
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Bunker, supra note 21, at 500.
Id.
Rees, supra note 16.
Id.
Id.
African Policymakers Must Pay More Attention to Counterfeit Drugs, supra note 94.
See Liang, supra note 2, at 324–25 (“[T]his fact [that prices are high] drives price-sensitive patients, such as
minorities, the uninsured, and seniors, to seek cheaper drugs from questionable sources.” (citation
omitted)).
For example, even with insurance, one American could not afford the $7,000 a year her insulin medicine
cost her, so she went to Mexico to get them for less than ten percent of the price. Wolfson, supra note 73.
Liang, supra note 2, at 325.
Blackstone et al., supra note 19, at 218; see also Bunker, supra note 21, at 497 (“In 1995, over 80 children
died in Haiti after taking acetaminophen syrup that had been made with glycerol contaminated with
ethylene glycol, an ingredient in antifreeze.”).
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with cystic fibrosis (CF), 122 a disease that can cause fast lung function decline when
someone with CF is exposed to bacteria. 123
Finally, women are also susceptible to the detriments of counterfeit drugs
when taking birth control medications. Access to pharmaceutical contraceptives is
still a challenge for some women. Even in the United States, close to twenty million
women either live in a contraceptive dessert or need publicly funded
contraception. 124 Further, the United States is one of forty-five countries that
requires a prescription to get the birth control pill. 125 When drugs are difficult to
get, people turn to online pharmacies, which is where counterfeit drugs are most
likely to become a problem. There are two prominent examples of counterfeit birth
control: (1) “in 1998, Brazil reported approximately 200 unwanted pregnancies from
the use of counterfeit contraceptive pills”; 126 and (2) in 2004 there was an FDA
warning about online pharmacies selling contraceptive patches containing no active
ingredient, which could then lead to unplanned pregnancy. 127 So, while this is a
global issue that has implications for everyone, some groups of people are more
likely to impacted by this crime.
II. POSSIBLE REMEDIES
Counterfeit goods are not new, and neither are attempts to stop them from
being sold. Other types of products mostly impact the manufacturer and do not put
the consumer in danger as counterfeit pharmaceuticals do. 128 Not only is this
problem dangerous, but it is also extremely costly to pharmaceutical companies.
There are major incentives for both the governments of impacted countries and
pharmaceutical companies to try to stop these drugs from reaching the consumers.
Pharmaceutical companies have recognized the significance of this problem and
have started their own ways of intervening, given that decades of government and
international attempts to remedy the problem have not been enough to stop the
problem. For example, Pfizer has a global security team to battle counterfeiters. 129
Also, Eli Lilly has invested over $100 million in combatting fake drugs by creating
traceable stamping codes for each of its products, allowing them to trace the drug
122
123

124

125
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127

128
129

Blackstone et al., supra note 19, at 218.
CYSTIC FIBROSIS FOUND., GERMS AND CYSTIC FIBROSIS: THE FACTS 3 (2020), https://www.cff.org/Life-WithCF/Daily-Life/Germs-and-Staying-Healthy/How-Can-You-Avoid-Germs/Resources/Germs-and-CF-TheFacts.pdf.
Birth Control Access, POWER TO DECIDE, https://powertodecide.org/what-we-do/access/birth-control-access
(last visited Nov. 19, 2019) (“Living in a contraceptive desert means that they lack reasonable access in
their county to a health center that offers the full range of contraceptive methods.”).
Sarah Wolfe, 8 Countries You Won't Believe Have It Backwards on Birth Control, SALON (Apr. 9, 2014),
https://www.salon.com/2014/04/09/8_countries_you_wont_believe_have_it_backwards_on_birth_control_part
ner/.
Bunker, supra note 21, at 497.
FDA and Johnson & Johnson Warn Public About Counterfeit Contraceptive Patches Sold Through Foreign
Internet Site, FDA NEWS (Feb. 4, 2004), http://www.fda.gov/bbs/topics/NEWS/2004/NEW01017.html.
See Blackstone et al., supra note 19, at 216–17.
Id. at 221.
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from being manufactured to finally reaching the patient. 130 While pharmaceutical
companies stepping in can improve safety for consumers, it causes them to spend
their money on these measures instead of research or lowering prices for customers.
A. Attempts by Individual Regions or Countries
i. Legislation in the United States
There have been a few key pieces of legislation relating to counterfeit drugs
in the United States that have helped keep it relatively (in comparison to the
countries just discussed) well-protected. First is the Prescription Drug Marketing
Act of 1987, which targeted the supply chain to protect Americans from counterfeit
drugs. 131 This law “provides that prescription drug products manufactured in the
United States and exported can no longer be reimported, except by the product’s
manufacturer,” while also setting uniform standards for distribution channels. 132
Obviously, this has not been fully effective, as over three decades later, there are
still counterfeit drugs making their way into our hospitals, mailboxes, and
pharmacies.
More recently enacted is the Drug Quality and Security Act, which was
signed into law in 2013 by President Obama. 133 The idea behind part of this Act is
to implement a “track-and-trace system” allowing a drug to be tracked from creation
to reaching the hands of the customer, which would make it more difficult for
counterfeit drugs to enter the supply stream. 134 This was broken down into two
phases: (1) pharmacies implementing a tracking system by 2015 and (2) putting
serial numbers on individual units by 2017. 135 While the idea behind this is
admirable as it targets one of the key problems—the supply chain—it is flawed in a
few ways and is not a panacea. First, it is still placing the cost burden on the
pharmaceutical companies, which ends up being paid for by the consumer. Second,
there are several troubling issues with the track-and-trace system that led to it
creating a false sense of security. The most common system used is the Radio
Frequency Identification (RFID) device, “which uses information stored and
remotely retrieved on transponders to provide automatic identification” and “can be
used to provide serial numbers to confirm the identity of a product.” 136 While better

130
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Jessica McLaughlin, The United States Isn’t Immune to Counterfeit Drugs, LAW STREET (May 8, 2015),
https://legacy.lawstreetmedia.com/issues/health-science/united-states-isnt-immune-to-counterfeit-drugs/.
Id.
Id.
Drug Quality and Security Act, Pub. L. No. 113-54, 127 Stat. 587 (2013). This Act “outlines critical steps to
build an electronic, interoperable system to identify and trace certain prescription drugs as they are
distributed in the United States.” McLaughlin, supra note 130.
Blackstone et al., supra note 19, at 218–19.
McLaughlin, supra note 130
Blackstone et al., supra note 19, at 219.
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than traditional pedigrees that are more easily forged, 137 implementing an RFID
system can be extremely expensive, costing manufacturers up to $25 million. 138 This
safety measure comes with a high cost, which may not be worth it if that cost drives
customers to unsafe, but cheaper, places to get their medicine.
The United States also has the Federal Food, Drug, and Cosmetic Act
(FDCA). According to this Act, a “counterfeit drug” is a drug, or the container or
labeling of a drug, that bears some mark, including a trademark, misidentifying its
“manufacturer, processor, packer, or distributor.” 139 The good thing about this Act is
that it criminalizes making, selling, or dispensing counterfeit drugs. 140 The bad
thing is that the penalties for violating this law are not severe enough to deter the
counterfeiters, especially when their business is so lucrative. Violators are punished
with a maximum $1,000 fine and up to one year in prison. 141 As stated earlier,
counterfeiters can make ten times more money than if they were trafficking
heroin. 142
ii. Attempted Remedies in Asia
Despite being the biggest culprits in counterfeit medicine, some Asian
countries are taking steps against counterfeit drugs. For example, Chinese officials
have begun investigating and closing factories associated with counterfeit drugs,
and the police even made arrests in a counterfeit drug conspiracy involving over
four million dollars’ worth of pills. 143 In October 2018, China’s Drug Administration
Law was reviewed to increase penalties for counterfeit drug makers. 144 China has
also developed stronger intellectual property laws that support both foreign and
domestic intellectual property rights (IPRs), 145 as shown in a “Chinese court
decision upholding Pfizer's patent rights to the blockbuster drug Viagra.” 146 In order
to remain strong in the global economic market, China will need to continue the
trend of enforcing IPRs to reduce counterfeiting. Despite increased enforcement in
China, there are already other countries in Asia that are beginning to become
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Id. § 333(a)(1).
Ehrenberg, supra note 53; see also Acri, supra note 41.
Bunker, supra note 21, at 500.
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appealing to the counterfeiters, showing that regional and global cooperation is
necessary to stop these criminals. 147
The other biggest culprit, India, is also making strides in the right direction
by introducing legislation mandating the barcoding of pharmaceutical products,
allowing fake drugs to be easily identified. 148 In 2018, India took this a step further
by deploying blockchain technology to improve the traceability of pharmaceutical
products by creating a database to keep track and help prevent fakes from entering
the supply chain. 149
Other countries have not taken such direct steps but are still attempting to
stop this problem. In Myanmar, they started using a “handheld device which can
assess the compound of a drug in real time.” 150 Other countries, such as Thailand,
Laos, and Cambodia, are addressing the consumers’ lack of awareness. 151
Governments and companies are issuing warnings, developing websites,
campaigning with multiple forms of media (posters, radio, and television), and
encouraging press coverage. 152 Instead of attempting to fix the complicated supply
chain, they are educating their citizens on safe purchasing habits, which is a
cheaper remedy that tackles the problem from a different angle.
iii. Attempts in Africa
One of the most important steps in stopping this illegal drug trade was the
establishing of the National Agency for Food and Drug Administration and Control
(NAFDAC) by the Nigerian Federal Ministry of Health. 153 NAFDAC had helped in
shutting down several counterfeit markets and slowed the importation of fake
medicine. 154 This program was an overall success, and Nigeria managed to reduce
counterfeit drug circulation by eighty percent by limiting drug importation to only
two locations and equipping customs officials with the resources to test whether the
drugs are authentic. 155 While this was not a perfect solution, as the counterfeit drug
147
148

149

150
151

152
153
154

155

Id.
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note 16.
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Paul N. Newton, Michael D. Green, Facundo M. Fernandez, Nicholas P.J. Day & Nicholas J. White,
Counterfeit Anti-infective Drugs, 6 LANCET: INFECTIOUS DISEASES 602, 609 (Sep. 2006),
https://www.sciencedirect.com/science/article/pii/S1473309906705813?via%3Dihub (“[I]n Laos, 63% of drug
sellers and 80–96% of consumers were not aware of the existence of poor quality drugs.”).
Id.
See Officials Boost Fight Against Counterfeit Drugs, NEW HUMANITARIAN (Apr. 6, 2007),
https://www.thenewhumanitarian.org/feature/2007/04/06/officials-boost-fight-against-counterfeit-drugs.
Gautam Naik, Nigerian Regulator Dodges Violence to Fight Fake Drugs: Dorothy Akunyili Speaks out
Against Bogus Medicines and Makers Lash Back, WALL ST. J. (May 28, 2004, 12:01 AM),
https://www.wsj.com/articles/SB108568995650123221.
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problem is still prevalent in Nigeria, it showed that steps can be taken to lessen the
severity of the issue.
The success of this program garnered attention and encouraged other African
nations to take action. For example, in 2018, Tanzania became “the first confirmed
country in Africa to achieve a well-functioning, regulatory system for medical
products.” 156 However, much of the progress in other countries has come from the
hard work of individuals or companies. One individual, Franck Verzefé, from
Cameroon, developed a portable device that uses artificial intelligence to help
hospitals and pharmacies determine if a drug is legitimate. 157 One of the most
helpful parts of his invention is the ability to build a database of information to
allow for more accurate and reliable data on the drug problems in Africa. 158 One
company, Mesdaf, is attempting to fix the supply chain by cutting out middlemen
and connecting manufacturers directly to hospitals and pharmacies. 159 Finally,
Ghana now has mPedigree, which “uses a simple text message code to help
customers verify the authenticity of medicines” and feasibly could be used in other
African countries. 160
B. International Collaboration
As counterfeit drugs are a global issue, it makes sense that there would need
to be international cooperation and collaboration to truly ameliorate this problem.
One of the most important international attempts at harmonization of IPRs was in
1994 when World Trade Organization (WTO) member countries signed the TradeRelated Aspects of Intellectual Property Agreement (TRIPS), which set the
minimum standards for IPRs. 161 At the time, it was thought to be a radical change
to the international market, but in practice it has not been as aggressive or strict as
imagined. 162 Compliance with TRIPS is not always easy or cheap. 163 Before the
agreement, many developing nations had very little intellectual property protection
or offered “no form of patent protection to pharmaceutical medicines.” 164 After the
agreement, these countries, many with public health crises, bear the cost of
implementing the agreement and the increase in drug costs that go with it. 165 Since

156
157
158
159
160

161
162
163
164
165

Atabong, supra note 106.
Id.
Id.
Neil Munshi, New Allies Fight Africa’s Deadly Scourge of Fake Medicines, FIN. TIMES (Sept. 23, 2019),
https://www.ft.com/content/ea9cbd66-c8c3-11e9-af46-b09e8bfe60c0.
Kwasi Gyamfi Asiedu, Ghana’s Budding Health Sector is Finally Getting Deserved Global Recognition,
QUARTZ AFR. (Apr. 18, 2019), https://qz.com/africa/1598303/skoll-awards-ghanas-mpharma-and-mpedigreewin-awards/; Munshi, supra note 159.
Bunker, supra note 21, at 507.
Sell, supra note 43, at 448.
Bunker, supra note 21, at 507.
Id.
Id.

2021]

Trademark Enforcement of Counterfeit Drugs

299

its implementation in 1994, TRIPS has not had a significant impact on stopping the
counterfeit drug crisis. 166
More recently, in June 2013, almost one hundred countries participated in a
global action––Operation Pangea VI––to help stop online trading of counterfeit
drugs. 167 Operation Pangea VI helped eliminate close to two thousand websites that
were selling illegal prescription drugs. 168 In July 2013, the Global Surveillance and
Monitoring System for SF medical products was launched. 169 This system works by
each country relaying information about the counterfeit drug to WHO, which then
adds it to a database in order to determine the scope of the problem, track patterns,
and keep the public informed. 170 While this is useful knowledge to have, the system
is fairly passive, does not take any actual steps in addressing the problem, and does
not allow the data to be freely accessed by the public. 171
III. STRONGER TRADEMARK ENFORCEMENT: A POSSIBLE SOLUTION OR AT LEAST A
STEP IN THE RIGHT DIRECTION?
Consumers are at the core of this whole problem, but that means they are
important in helping to stop the issues. Many attempts by governments and
pharmaceutical companies have so far only addressed the supply side with the
complicated supply chain, which has not been a perfect solution due to its high level
of complication and high costs. On the other hand, it could be cheaper and more
effective to try to control what the consumer already knows—the appearance of
their medicine and the trademarked information associated with it. For brand name
drugs, trademarks are especially important as they convey to the customer that
their product is high quality and one to be trusted. 172 Trademarks seek to protect
exactly what counterfeiters target: brand recognition. 173 Medicines can have many
different trademarks. Marks can be obtained on the name, design, and symbols on
the packaging, along with the color and shape of the pill. 174 In this way,
pharmaceutical companies can protect every unique aspect of the appearance of
their medicine in addition to any other intellectual property the company has for
the drug. 175
166
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Typically, patents on pharmaceuticals are the first line of defense, but in
practice, they are less effective at stopping counterfeiters. 176 As discussed in Part I,
the counterfeit drugs are not a copy of the active ingredient (what would be
patented) but are imposters made of cheaper ingredients. 177 Further, trademark
protection is available to generic drug manufacturers whereas patent rights are
not. 178 Unlike in many patent lawsuits, “in many countries trademark owners can
have the counterfeit goods and accompanying documents, and even sometimes
manufacturing equipment immediately seized at the outset of [a] lawsuit,” allowing
for quicker relief than waiting for a decision in a patent trial that could last
years. 179 Finally, trademarks are the cheaper option and are usually less time
consuming than patent prosecution or litigation. 180 Especially for developing
countries that need quicker relief and have fewer resources to expend on securing
and enforcing IPRs, trademarks seem to be the better remedy.
In an ideal world, these trademarks on pharmaceuticals would be strictly
enforced, and knockoffs would be prosecuted and removed from the market.
However, it is not that simple. Right now, many consumers are buying counterfeit
drugs believing them to be legitimate, and they are doing so due to the high-quality
packaging and appearance of the counterfeit medicine, making it difficult,
sometimes impossible, for consumers to be able to spot fake drugs. 181 In order for
companies, especially in developing countries, to invest in trademark protection,
they need assurance that they are not wasting their money on something that will
not be enforced, and if it is enforced, it will have meaningful relief for them. With
stronger trademark enforcement comes more trust from consumers and companies,
which will both deter people from buying fake drugs and encourage companies to
develop their trademark portfolios.
In the United States, trademark owners have had federal causes of action
against unauthorized use of their marks for many years now. 182 However, there is
not strong enough enforcement against counterfeit trademarked goods in the United
States as the laws do not wholly cover every instance of counterfeiting, which is
needed to stop this problem. There are two primary federal statutes, the Lanham
Act 183 and the 1984 Trademark Counterfeiting Act (TCA), 184 that created civil and
criminal liability for trademark infringement. These statutes “define the term
‘counterfeit’ vaguely and broadly.” 185 A counterfeit trademark is a “‘spurious mark’
that is ‘identical with, or substantially indistinguishable from, a registered mark,’
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and whose use is ‘likely to cause confusion.’” 186 The Lanham Act is a broad
trademark regulator and created civil causes of action for infringement of both
registered and unregistered marks. 187 The TCA, amended by the 2005 Stop
Counterfeiting in Manufactured Goods Act, took trademark enforcement a step
further with the addition of criminal penalties for the most serious forms of
infringement, which Congress considered to be the intentional trafficking of
counterfeit goods. 188 The penalties under this act are fines up to $5 million and 10
years imprisonment. 189
In the case of counterfeit drugs, this criminalization is beneficial as it targets
the trafficking of counterfeit drugs, which is the primary problem in America given
that most of the drugs making it to consumers come from overseas and are illegally
trafficked into the country. In theory, the TCA would be able to stop all criminals
trafficking these fake drugs, but the broad definition of a counterfeit mark makes
this more difficult. Under the TCA a counterfeit mark is one:
(i) that is used in connection with trafficking in any goods, services,
labels, patches, stickers, wrappers, badges, emblems, medallions,
charms, boxes, containers, cans, cases, hangtags, documentation,
or packaging of any type or nature;
(ii) that is identical with, or substantially indistinguishable from, a
mark registered on the principal register in the United States
Patent and Trademark Office and in use, whether or not the
defendant knew such mark was so registered;
(iii) that is applied to or used in connection with the goods or services
for which the mark is registered with the United States Patent
and Trademark Office, or is applied to or consists of a label, patch,
sticker, wrapper, badge, emblem, medallion, charm, box,
container, can, case, hangtag, documentation, or packaging of any
type or nature that is designed, marketed, or otherwise intended
to be used on or in connection with the goods or services for which
the mark is registered in the United States Patent and Trademark
Office; and
(iv) the use of which is likely to cause confusion, to cause mistake, or
to deceive. 190
When the law was passed, Congress noted that the “definition of
‘substantially indistinguishable’ will have to be elaborated on a case-by-case basis
by the courts.” 191 The “courts have been reluctant to label a mark a counterfeit, at
least in the word mark context, when defendant’s mark is not a fairly clear copy of
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the registered trademark.” 192 For example, in one case, the court analyzed a claim
that a Chinese toothpaste was counterfeit because it was in a red box labeled
“Colddate” and held that, although the products were “quite similar,” they were not
“substantially indistinguishable.” 193 There seems to be a very fine line between
infringement and counterfeit, and marks are less likely to be determined counterfeit
if they are not identical images of the original trademark. 194 If anything, this
encourages counterfeiters to make convincing fake packaging to still trick
consumers without making it identical so they can escape criminal liability. In order
for the TCA to help remedy the counterfeit drug issue, the definition of counterfeit
and the implementation of this definition need to cover both the identical copies and
those that are still close enough to trick the consumer.
Although some instances of pharmaceutical counterfeiting fall under the
Lanham Act or TCA, there are still situations where the criminal will escape
liability. The laws combatting fake drugs, discussed earlier, offer much weaker
remedies with “tepid” penalties and no relief to those harmed by the drug. 195 Due to
the extreme danger posed by fake pharmaceuticals, the penalties under the fake
drug laws are inadequate, and trademark enforcement has been unable to ensure
enforcement in every case. 196
In addition to trying to control the supply chain, other countries should
implement their versions of laws criminalizing counterfeit drug trafficking or the
use of counterfeit marks on pharmaceutical products. Especially for developing
countries, trademarks are an affordable form of intellectual property that
consumers are able to identify and trust. With enforcement of these marks,
countries can keep copycat drugs from reaching consumers while still punishing the
perpetrators. The Madrid Protocol of 1989, which helped streamline international
trademark registration between its member countries, allows someone to complete
one international application and receive protection in participating countries that
approve the mark as determined by their domestic law. 197 In order to encourage and
help developing countries, the international fee is lowered to ten percent for
applications originating in the least developed countries as defined by the United
Nations. 198 The Madrid Protocol emphasizes the importance of international
enforcement of trademarks but still relies on each individual country to enforce
trademark laws. In some countries, their laws are still outdated and do not
recognize this international system, so enforcement is even more of an issue.
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CONCLUSION
In conclusion, there truly is not one solution for this problem. Greater
harmonization and coordination internationally are required. Each country faces
unique issues with specific diseases and the amount of money it can spend on
protecting and enforcing intellectual property rights. Because counterfeit drugs are
such a global issue, it is often difficult to pinpoint the source of the fake drug and
find the criminals behind its creation and distribution. While trademarks are not a
cure-all, they are a feasible first start for many countries. Trademark enforcement
has not been perfect in America, but it is one aspect that has allowed the country to
have the safest drug supply in the world. If consumers are educated on this issue, or
at least warned about fake drugs, they are likely to be more cautious shoppers,
which could lead to them making safer decisions on where to get their medicine and
being skeptical of knock-off products.

